Pipeline

Emergex has a growing pipeline of CD8+ T cell Adaptive Vaccine candidates. We have initiated first-in-human Phase I clinical trials conducted in Switzerland for Dengue Fever and COVID-19 vaccine candidates. We are also actively developing our programmes for seasonal Influenza and Chikungunya through active preclinical work supported by partner organisations.